Advertisement

Topics

WHO: Merck's experimental Ebola vaccine shows 97.5% efficacy in Congo

06:31 EDT 16 Apr 2019 | SmartBrief

The World Health Organization announced that the experimental Ebola virus vaccine V920 developed by Merck, which is being tes -More

Original Article: WHO: Merck's experimental Ebola vaccine shows 97.5% efficacy in Congo

NEXT ARTICLE

More From BioPortfolio on "WHO: Merck's experimental Ebola vaccine shows 97.5% efficacy in Congo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Marburg and Ebola Virus Infections
Ebola virus and Marburg virus are related viruses that cause hemorrhagic fevers — illnesses marked by severe bleeding (hemorrhage), organ failure and, in many cases, death. Both viruses are native to Africa, where sporadic outbreaks have occurred f...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...